CASRN 106-99-0 | DTXSID3020203


On this page:

Notice - This site contains archived material(s)

Archive disclaimer
Archived files are provided for reference purposes only. The file was current when produced, but is no longer maintained and may now be outdated. Persons with disabilities having difficulty accessing archived files may contact the Risk Webmaster for assistance. Please use the contact us form if you need additional support.


1,3-Butadiene has been shown to be an indirect mutage in bacteria. Two of its potential metabolites, 3,4- epoxybutene and diepoxybutane, are genotoxic in prokaryote as well as eukaryote test systems. Exposure of rodents to 1,3-butadiene results in ovarian tumors in mice and testicular tumors in rats, which offers suggestive evidence that 1,3-butadiene (or a motabolite of 1,3-butadiene) may reach the germ cells. There is also evidence that the dimer of 1,3-butadiene, 4-vinyl-1-cyclohexene, causes ovarian tumors in mice. The total body of evidence, including metabolism, mutagenicity and carcinogenicity data, suggests that 1,3-butadiene may present a genetic risk to humans. However, mutagenicity studies in mammalian test systems should be conducted to further characterize the mutagenic potential of 1,3-butadiene. On the basis of sufficient evidence from studies in two species of rodents, and inadequate epidemiologic data, 1,3-butadiene can be classified, according to EPA's Proposed Guidelines for Carcinogen Risk Assessment, as a 'probable' human carcinogen, Group B2. Using the classification scheme of the International Agency for Research on Cancer, 1,3-butadiene would be classified as a 'probable' human carcinogen, Group 2B.


Bayard, S., R. Beliles, A. Chiu, H. Gibb, AND B. Sadler. MUTAGENICITY AND CARCINOGENICITY ASSESSMENT OF 1,3-BUTADIENE. U.S. Environmental Protection Agency, Washington, D.C., EPA/600/8-85/004F (NTIS PB86125507).

Top of Page

Additional Information

See also PB85-181097.

Top of Page


If you have a disability and the format of any material on our web pages interferes with your ability to access the information, please reach out to us using the Contact Us about IRIS form for assistance. To enable us to respond in a manner most helpful to you, please indicate the nature of the accessibility problem, the web address of the requested material, your preferred format in which you want to receive the material (electronic format (ASCII, etc.), standard print, large print, etc.), and your contact information.

Top of Page